life scienc tool diagnost
ep ahead consensu synh ep exceed
estim better revenu profit factor
line neg impact ep addit increas
ep guidanc midpoint vs consensu
rais ep reflect latest beat
top-line profit upsid book stronger plan clinic qtrli
revenu rose ahead estim
exceed expect commerci cc
nomin higher view quarterli basi clinic
net btb ahead estim commerci
quarterli net btb fell short expect gross
margin expand sg declin adj ebitda
margin rose ahead plan gener million
cash help fund million debt pay million share
repurchas reserv stand million net leverag ratio
share rise encourag healthi oper beat
strengthen quarterli clinic book call commentari point
new sizeabl clinic strateg partnership contribut
meaning importantli new relationship win deriv
current commerci relationship testament build traction across
syneo one combin offer contribut million new
busi win ytd ep share trade
signific discount peer contribut part
outperform risk shift demand commerci volatil integr
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
global contract research organ cro oper
clinic drug develop commerci market
follow merger inventiv health second largest
cro largest contract commerci organ
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky scenario assum continu
industri lead growth sustain rel superior profit
larg pharma client sizabl project award lower
expect cancel continu strength spend
outsourc demand cross-sel opportun relat
merger inventiv health aug
grey sky scenario assum deceler
growth declin profit trajectori share loss weaken
demand small/mid-s biotech custom increas
cancel custom consolid headwind relat
inventiv integr slowdown spend
 close
compani mention price
